AACR 2024

M3554, a Novel Anti-GD2 Antibody Drug Conjugate

Amendt | Oral #ND08

Machine Learning—Spatial Quantification of the Tumor Microenvironment Identifies Differences Associated with Response to Bintrafusp Alfa vs. Pembrolizumab Treatment in Phase 3 INTR@PID Lung 037 Study

Abel | Poster #6179

Combined Inhibition of ART and ATM with Tuvusertib and Lartesertib (M4076) Impacts the Tumour Microenvironment

Laaber | Poster #5617

In Vitro Evaluation of Myelosuppressive Effects of the ATRi Tuvusertib and ATMi Lartesertib (M4076), Alone and in Combination

Mukker | Poster #7186

First-in-Human Trial of TIGIT Inhibitor M6223 as Monotherapy or in Combination with Bintrafusp Alfa (BA) in Patients with Advanced Solid Untraceable Tumors

Naing | Poster #CT184

A Phase 1 Study of the IAP Inhibitor Xevinapant (Debio 1143) to Evaluate Food Effect and Drug-Drug Interactions with a Proton Pump Inhibitor in Healthy Volunteers

Nicolas-Métral | Poster #CT140

Preclinical Efficacy and Safety of M9140, a Novel Antibody-Drug Conjugate (ADC) with Topoisomerase 1 (TOP1) Inhibitor Payload Targeting Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5 (CEACAM5)-Expressing Tumors

Raab-Westphal | Poster #2362

Phase Ib Trial of ATRi Tuvusertib + ATMi Lartesertib (M4076) in Patients with Advanced Solid Tumors

Siu | Poster #CT063

M9657, a Tumor-Targeted CD137 Agonist, Induced Significant Antitumor Immunity in Combination with Anti-PD-1 Antibody

Xu | Poster #5305

Extended Treatment with IAP inhibitor Xevinapant Post Radiotherapy Improves Therapeutic Efficacy and Promotes Antitumor Immunity in Preclinical Models

Yeung | Poster #2921